Synthon Successfully Concluded Phase I Clinical Trial for Trastuzumab
Synthon’s first truly biosimilar product now embarking on phase III study
All in vitro and in vivo studies conducted so far showed biosimilar behavior of Synthon’s trastuzumab in comparison with the reference product, Herceptin®. The outcome of the phase I clinical trial confirmed these results, showing bio-equivalence of Synthon’s trastuzumab to Herceptin®.
“Trastuzumab is one of the most advanced biopharmaceutical products of Synthon’s pipeline, and is now ready to go into a confirmatory phase III clinical trial in breast cancer patients,” says Rudy Mareel, CEO Synthon. “Biosimilars are to Synthon a serious stepping stone towards the development of biosuperior and truly innovative biological products. We are very excited about our growing portfolio of new biological antiproliferative agents that is well positioned next to our biosimilars.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.